STOCK TITAN
  1. Home
  2. News
  3. ELOX

Eloxx Pharmaceut - ELOX STOCK NEWS

Welcome to our dedicated page for Eloxx Pharmaceut news (Ticker: ELOX), a resource for investors and traders seeking the latest updates and insights on Eloxx Pharmaceut stock.

Eloxx Pharmaceuticals, Inc. (ELOX) is a clinical-stage biopharmaceutical company developing RNA-modulating therapies for rare genetic disorders caused by nonsense mutations. This page provides authorized news updates and official announcements regarding clinical developments, regulatory milestones, and corporate progress.

Investors and stakeholders will find timely updates on key initiatives including clinical trial results, FDA designations, and research collaborations. Our curated news collection covers essential categories:

• Clinical program advancements for lead candidates ELX-02 and ZKN-013
• Regulatory updates including Orphan Drug Designations
• Strategic partnerships in genetic therapy development
• Financial disclosures and corporate communications

All content is sourced directly from company filings and verified press releases. Bookmark this page for reliable updates on Eloxx's innovative approach to addressing unmet needs in rare diseases through targeted RNA modulation therapies.

News

Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update

Rhea-AI Summary
Eloxx Pharmaceuticals announced positive results from its Phase 2 clinical trial of ELX-02 for the treatment of Alport syndrome. All three patients showed improvement in kidney biopsies, demonstrating the disease-modifying effect of ELX-02. Eloxx plans to advance ELX-02 into a pivotal trial for Alport syndrome. In addition, the company received FDA clearance to begin a study of ZKN-013 and raised $3.4 million in net proceeds through an equity offering program. Eloxx also received an extension from Nasdaq to regain compliance with listing requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.63%
Tags
earnings
-
News

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Rhea-AI Summary
ELX-02 shows improvement in podocyte foot process effacement in Alport syndrome patients, supporting decision to advance into pivotal trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.63%
Tags
clinical trial
-
News

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Rhea-AI Summary
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) has received an extension from the Nasdaq Listing Qualifications Panel to regain compliance with the minimum market value of listed securities requirement. The extension, until October 9, 2023, will allow the company to execute its plan to meet Nasdaq's standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.32%
Tags
none
News

Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit

Rhea-AI Summary
Eloxx Pharmaceuticals has announced the publication of a study demonstrating the potential of its TURBO-ZM chemistry technology platform to develop novel Ribosome Modulating Agents (RMAs) for the treatment of colorectal cancer. The study shows that the novel RMA, ZKN-157, has demonstrated activity against subtypes of colorectal cancer, particularly the CMS2 subtype characterized by high MYC activity. This research opens up opportunities to selectively target MYC-driven cancers with a novel mechanism and potentially synergize with existing cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.01%
Tags
none
-
News

Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
clinical trial
-
News

Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.69%
Tags
conferences
News

Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.69%
Tags
none
-
News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.88%
Tags
clinical trial
-
News

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
News

Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.53%
Tags
clinical trial
Stock ELOX logo
Eloxx Pharmaceut

Nasdaq:ELOX

ELOX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ELOX Stock Data

314
2.90M
5.98%
19.58%
0.7%
Biotechnology
Healthcare
Link
United States
Watertown